12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Regorafenib: Additional Phase III data

Additional data from the double-blind, international Phase III GRID trial in 199 patients showed that oral regorafenib plus best supportive care (BSC) non-significantly improved OS, a secondary endpoint, vs. placebo plus BSC (HR=0.772, p=0.199). Bayer said the OS endpoint did not reach statistical significance due to the crossover design of the trial in which patients who received placebo were eligible to receive regorafenib following disease progression. Additionally, regorafenib plus BSC significantly improved DCR vs. placebo plus BSC (52.6% vs. 9.1%, p<0.000001). The trial enrolled patients with metastatic and/or unresectable GIST whose...

Read the full 435 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >